Business Description
Korro Bio is a US-based biotech company focused on treating serious diseases by editing RNA, a process that modifies genetic instructions within the body without permanently altering DNA. Its lead program targets hyperammonemia, a dangerous buildup of ammonia in the blood, while other efforts address conditions such as Parkinson's disease, ALS, and certain pain disorders. The company works with Novo Nordisk to develop treatments for heart and metabolic diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, Korro Bio continues to build its pipeline around its proprietary RNA editing technology.
